Navigating Clinical Trials: Essential Knowledge for Dermatologists-Practical Points in Psoriasis Studies

Video Transcription

Video Summary

Dr. April Armstrong, a UCLA professor and chief of dermatology, shares insights on psoriasis clinical trials, which she's worked on for over 20 years. Her talk focuses on understanding inclusion and exclusion criteria, endpoints, and analysis methods in these studies, enabling better interpretation of trial results. Key inclusion criteria for systemic medications in moderate to severe plaque psoriasis often include a POSI score of 12 or more and BSA of at least 10%. Exclusion criteria usually rule out those with significant infections or psychiatric conditions. In terms of endpoints, systemic medications typically look at POSI-90 and clear or almost clear IgA. Dynamic endpoints assess changes over time, while static endpoints provide specific targets. Analysis methods like indirect comparisons help when no direct head-to-head trials are available, often using network meta-analysis to compare treatments indirectly. Understanding these aspects is crucial for evaluating and comparing clinical trial results effectively.

Asset Subtitle

by April Armstrong, MD, MPH, FAAD

Meta Tag

Concept Plaque Psoriasis

Concept Trial Endpoint

Concept Clinical Trial Inclusion Criteria

Concept Clinical Trial Exclusion Criteria

Concept PASI

Keywords

psoriasis clinical trials

inclusion criteria

exclusion criteria

endpoints

systemic medications

network meta-analysis

Plaque Psoriasis

Trial Endpoint

Clinical Trial Inclusion Criteria

Clinical Trial Exclusion Criteria

PASI